Piper Jaffrey raised Geron's price target from $5 to $10

Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply
Fishermangents
Site Admin
Posts: 531
Joined: Thu Dec 03, 2015 3:39 pm

Piper Jaffrey raised Geron's price target from $5 to $10

Post by Fishermangents » Mon Dec 07, 2015 7:14 pm

7 Dec 2015

Piper Jaffray on Monday issued a company note on Geron Corporation (NASDAQ: GERN) after news of new drug developments at the ASH 2015 conference. Piper Jaffray rates Geron as Overweight and raised the company's price target from $5.00 to $10.00.
Analysts Charles Duncan and Sarah Weber wrote, “With two strategically designed Phase II studies in high unmet needs (SOC-failed MF and MDS), we believe enrollment progress and data in the next 12-24 months could generate significant value creation...The activity observed to date... is seen by clinical researchers as one of the most promising emerging, novel mechanisms in the field, and fully supportive of advancement to later stage trials.”

source: https://finance.yahoo.com/news/piper-ja ... 23900.html

Post Reply